Larimar Therapeutics
LRMRLarimar Therapeutics is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases using its proprietary cell-penetrating peptide (CPP) technology platform.
Table of contents
Earnings
Next report
Aug 13, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Larimar Therapeutics is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases using its proprietary cell-penetrating peptide (CPP) technology platform. The company's primary focus is on protein replacement therapies that deliver essential molecules directly to intracellular targets, such as the mitochondria. Its lead program aims to address the underlying protein deficiency in Friedreich's ataxia, a progressive and fatal genetic disorder.
Larimar is a pioneer in systemic frataxin replacement therapy, holding multiple regulatory designations including FDA Breakthrough Therapy and EMA PRIME status.
Questions, answered.
- What is Larimar Therapeutics's market cap?
- Larimar Therapeutics (LRMR) has a market capitalization of $429.0M and trades on NASDAQ.
- Who are Larimar Therapeutics's competitors?
- Larimar Therapeutics's key competitors include Biogen Inc., PTC Therapeutics, Inc., Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Larimar Therapeutics headquartered?
- Larimar Therapeutics is headquartered in United States of America and employs approximately 42 people. It has been publicly traded since 2020.